Gradient Investments’s Amneal Pharmaceuticals AMRX Stock Holding History

Gradient Investments’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-41	Closed	–	–	1090
2019 Q3	$0	Buy	+41	New	+$143	﹤0.01%	1103

Other funds holding AMRX

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gradient Investments's AMRX Position: Q4 2019 in Review

Gradient Investments sold out of Amneal Pharmaceuticals (AMRX) in Q4 2019, closing a stake of 41 shares.

Gradient Investments first reported a position in AMRX in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 129 funds tracked by Wall St. Rank hold AMRX as of Q4 2019.

Gradient Investments reported no remaining Amneal Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Gradient Investments sold 41 Amneal Pharmaceuticals shares in Q4 2019.
Gradient Investments first reported a position in Amneal Pharmaceuticals in Q3 2019 and held it in 1 quarter.
Gradient Investments's Amneal Pharmaceuticals position peaked at $0 in Q3 2019.
129 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2019.

Based on Gradient Investments's 13F filing for Q4 2019, filed 15 Jan 2020.